文献速递乳腺癌消化系统肿瘤

芳香化酶抑制剂与绝经后乳腺癌患者结直肠癌风险

Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

基于英国临床实践研究数据链的队列研究,纳入1996至2015年间新接受芳香化酶抑制剂或他莫昔芬治疗的55岁以上乳腺癌女性,随访至2016年。结果显示,与他莫昔芬相比,芳香化酶抑制剂未增加结直肠癌风险(调整HR 0.90,95%CI 0.53-1.52),且与累积用药时长及起始后时间无关。

要点

  • 芳香化酶抑制剂对比他莫昔芬未增加结直肠癌风险,调整HR为0.90。
  • 结直肠癌发病率两组均为150/10万人年。
  • 累积用药时长和起始后时间均未见风险关联。

核心结论

  • 在绝经后乳腺癌女性中,芳香化酶抑制剂的使用与他莫昔芬相比未增加结直肠癌风险。

研究设计与样本

  • 基于英国临床实践研究数据链的队列研究,纳入1996年1月1日至2015年9月30日间新接受芳香化酶抑制剂或他莫昔芬治疗的55岁及以上乳腺癌女性,随访至2016年9月30日。
  • 共9701例起始芳香化酶抑制剂和8893例起始他莫昔芬作为一线内分泌治疗,中位随访分别为2.4年和2.9年。
  • 采用高维倾向评分调整的Cox比例风险模型估计风险比,所有暴露滞后1年。

主要发现

  • 芳香化酶抑制剂组与他莫昔芬组的结直肠癌发病率均为150/10万人年。
  • 与他莫昔芬相比,芳香化酶抑制剂与结直肠癌风险的调整HR为0.90(95%CI 0.53-1.52)。
  • 累积用药时长(P-异质性=0.54)和起始后时间(P-异质性=0.66)均无显著关联。

临床怎么用

  • 该人群研究结果可为关注芳香化酶抑制剂结直肠癌安全性的临床医生和患者提供 reassurance。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A large trial of postmenopausal women with breast cancer reported an imbalance in colorectal cancer events with aromatase inhibitors (AIs), compared with tamoxifen in the adjuvant setting. This unexpected signal was observed within 3 years of randomization. To date, no observational studies have examined this important safety question in the natural setting of clinical practice. Thus, the objective of this study was to determine whether AIs, when compared with tamoxifen, are associated with increased risk of colorectal cancer in postmenopausal women with breast cancer. PATIENTS AND METHODS: Using the UK Clinical Practice Research Datalink, we identified women, at least 55 years of age, with breast cancer newly treated with either AIs or tamoxifen between 1 January 1996 and 30 September 2015, with follow-up until 30 September 2016. High-dimensional propensity score-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of incident colorectal cancer associated with AIs when compared with tamoxifen overall, by cumulative duration of use, and time since initiation. All exposures were lagged by 1 year for latency considerations. RESULTS: A total of 9701 and 8893 patients initiated AIs and tamoxifen as first-line hormonal therapy (median follow-up of 2.4 and 2.9 years, respectively). Compared with tamoxifen, AIs were not associated with an increased risk of colorectal cancer (incidence rates of 150 per 100 000 person-years in both groups; adjusted HR: 0.90, 95% CI: 0.53-1.52). Similarly, there was no evidence of an association with cumulative duration of use (P-heterogeneity = 0.54), and time since initiation (P-heterogeneity = 0.66). CONCLUSIONS: In this first population-based study, the use of AIs was not associated with an increased risk of colorectal cancer. These findings should provide reassurance to the concerned stakeholders.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Khosrow-Khavar F, Yin H, Barkun A, et al. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer. Ann Oncol. 2018. PMID: 29293897. doi:10.1093/annonc/mdx822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。